Christina Tsalapaki

Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study

Antonis Fanouriakis, Christina Adamichou, Sofia Koutsoviti et al. · Seminars in Arthritis and Rheumatism · 2018 · 77 citations

Life Sciences, Immunology, Pharmacotherapy +17

Clinical and financial burden of active lupus in Greece: a nationwide study

E. Karampli, Prodromos Sidiropoulos, Irini Gergianaki et al. · Lupus · 2016 · 26 citations

Medicine, Health Policy, Internal Medicine +17

Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis

Kalliopi Klavdianou, Argyro Lazarini, Alexandros Grivas et al. · Frontiers in Medicine · 2020 · 22 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +14

Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment

Κonstantinos Thomas, Emilia Hadziyannis, Chrisoula Hatzara et al. · Pathogens and Immunity · 2020 · 15 citations · Full text

Medicine, Immunology, Internal Medicine +15

Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis

Christina Tsalapaki, Argyro Lazarini, Evaggelia Argyriou et al. · Rheumatology International · 2024 · 11 citations · Full text

Life Sciences, Internal Medicine, Pharmacotherapy +14